Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Keith T Flaherty

ECOG-ACRIN Cancer Research Group

Intervention

Adavosertib(drug)

Enrollment

6452 enrolled

Eligibility

18 years · All sexes

Timeline

2015 – 2026

Study locations (20)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Thomas Hospital, Fairhope, Alabama, United States
• Mobile Infirmary Medical Center, Mobile, Alabama, United States
• University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Regional Hospital, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
• +5 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Mantle cell lymphoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07377578
  A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
  Guangzhou Lupeng Pharmaceutical Company LTD.
• RECRUITINGPHASE2NCT07272499
  Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
  Ruijin Hospital
• RECRUITINGPHASE2NCT07029737
  A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
  AstraZeneca
• RECRUITINGNANCT07257510
  Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
  Peking University Third Hospital
• RECRUITINGPHASE2NCT06846489
  Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
  Sun Yat-sen University
• RECRUITINGPHASE3NCT06742996
  A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
  BeOne Medicines
• RECRUITINGNCT06788652
  A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• RECRUITINGPHASE2NCT06522386
  GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
  M.D. Anderson Cancer Center

See all trials for Mantle cell lymphoma →